{"id":"placebo-mim8","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5314670","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, Mim8 contains no active pharmaceutical ingredient and serves as a comparator arm in phase 3 clinical trials. It allows researchers to distinguish genuine drug effects from placebo response and natural disease progression. The specific formulation and indication for this Novo Nordisk placebo are not publicly disclosed in standard pharmaceutical databases.","oneSentence":"Placebo (Mim8) is an inert control substance used in clinical trials to establish baseline efficacy and safety comparisons.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:01.354Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04204408","phase":"PHASE2","title":"A Research Study Investigating Mim8 in People With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-10","conditions":"Healthy Volunteers, Haemophilia A With or Without Inhibitors","enrollment":275},{"nctId":"NCT05127473","phase":"PHASE1","title":"A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-07-14","conditions":"Healthy Volunteers - Haemophilia A","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (Mim8)","genericName":"Placebo (Mim8)","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mim8, also known as NNC0365-3769, is a Factor VIIIa-mimetic antibody being studied in clinical trials for conditions such as Haemophilia A. It is administered in various concentrations, including 10 mg/mL and 100 mg/mL, and is compared to a placebo in these trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}